Results 51 to 60 of about 20,052 (248)

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases [PDF]

, 2016
Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new ...
Holscher, Christian, Li, Lin, Li, Yanwei
core   +1 more source

Selenoprotein H Functions as a PPARα Coactivator to Link Selenium Homeostasis to Hepatic Lipid Metabolism and Protect against Steatohepatitis

Advanced Science, EarlyView.
Our study identifies selenium deficiency as a hallmark of MASH pathogenesis. Dietary selenium supplementation enhances hepatic fatty acid oxidation (FAO) and attenuates MASH progression by activating the PPARα pathway via selenoprotein H (SELENOH). This selenium‐SELENOH‐PPARα nexus redefines the functional scope of selenoproteins, moving from redox ...
Yuwei Zhang, Yuchen Wang, Binbin Li, Xin Li, Chenyu Liu, Yanhao Chen, Cheng Tian, Dongmei Wang, Xiaosong Gu, Chunping Jiang, Yuda Wei, Qiurong Ding   +11 more
wiley   +1 more source

Reflections on the Sulphonylurea Story. A Drug Class at Risk of Extinction?:Or A Drug Class Worth Reviving? [PDF]

, 2019
The role of sulphonylureas (SUs) in modern clinical practice poses ongoing clinical debate. With the advent of newer agents in diabetes management, there is an increasing shift away from the prescribing of SUs, but not necessarily to more effective ...
Janbon M, Loubatieres A, Mailhot J, Rados DV, The University Group Diabetes Program   +4 more
core   +2 more sources

Piperazine‐Functionalized Nanoparticles Enable Oral Insulin Delivery in Obese Mice

Advanced Science, EarlyView.
ABSTRACT Biologics have gained prominence as a rapidly advancing therapeutic modality for a diverse spectrum of medical conditions. Nonetheless, they are predominantly administered parenterally due to poor absorption through the gastrointestinal tract. Additionally, repeated injections of biologics such as insulin cause injection pain, leading to dose ...
Yuxue Cao, Xiaofan Jiang, Md Moniruzzaman, Alexandra Mueller, Taskeen Iqbal Janjua, Nisha Tyagi, Zhi Qu, Kuan Yau Wong, Yuran Feng, Aayushi Ghodasara, Ekaterina Strounina, Benjamin P. Ross, Tushar Kumeria, Sumaira Z. Hasnain, Amirali Popat   +14 more
wiley   +1 more source

Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data

Biomedicines
Once-weekly semaglutide is a widely used glucagon-like peptide-1 receptor agonist (GLP-1RA) used for the treatment of type 2 diabetes (T2D). In clinical trials, semaglutide improved glycemic control and obesity, and reduced major cardiovascular events ...
Hisayuki Katsuyama, Mariko Hakoshima, Emika Kaji, Masaaki Mino, Eiji Kakazu, Sakura Iida, Hiroki Adachi, Tatsuya Kanto, Hidekatsu Yanai   +8 more
doaj   +1 more source

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists [PDF]

, 2014
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a ...
Andrei C Sposito, Francisco Kerr Saraiva
core   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +14 more
wiley   +1 more source

Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION The evoke/evoke+ trials are investigating semaglutide in a population with early Alzheimer's disease (AD). Specific analyses of semaglutide safety data in older adults are limited; therefore, in the current analysis, we aimed to evaluate ...
Marwan Sabbagh, Cristina Boschini, Sharon Cohen, Magnus Fugger, Frank Jessen, Sune Dandanell, Sue D. Pedersen, Luis Rafael Solís Tarazona, Vanita R. Aroda   +8 more
doaj   +1 more source

Semaglutide for the treatment of obesity [PDF]

, 2022
Introduction and purpose Due to the growing tendency to diagnose obesity in patients, scientists are trying to find drugs that facilitate weight reduction.  An example of such a formulation is the GLP-1 analogue semaglutide. The following article is
Gras-Ozimek, Jordi, Kozińska, Iga, Kozińska, Urszula, Oleszczuk, Anna, Rafal   +4 more
core   +2 more sources

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source